Skip to main content

Alzheon Phase II

All trials

Alzheimer

Alzheon Phase II

Leeftijd icoon
50 - 80 years (M / F)
Diagnose icoon
Mild Cognitive Impairment (MCI) due to Alzheimer's, light-stage Alzheimer's and carrier of APOE e4 gene.
Duratie onderzoek
About 2 years
Locatie icoon
Amsterdam, Den Bosch and Zwolle

About this research

In order to participate in this study, you must be able to speak and read Dutch fluently.

A phase II, multicenter, study of the effects of the research drug ALZ-801 on biomarkers involved in the progression of Alzheimer’s disease.

The target population for this study is men and women aged 50 to 80 years who are diagnosed with Mild Cognitive Impairment due to Alzheimer’s disease (MCI) or mild-stage Alzheimer’s disease and who are carriers of the e4 variant of the APOE gene.

In this study, the researchers want to learn more about the effectiveness, mode of action, safety, and tolerability of ALZ-801.

The research drug PQ912 is a new drug against Alzheimer’s disease. With this study, the researchers want to learn more about the safety, workings, and effectiveness of the drug.

The research is carried out by Brain Research Center Amsterdam, Den Bosch, and Zwolle. The study consists of 3 phases with the possibility to participate in a sub-study.

This study is commissioned by Alzheon.

This text has been directly translated from the Dutch trial description as approved by the Ethical Committee.

Screening – Selection

During 2 visits during the 4-week screening period, it is determined whether you meet the study criteria and whether your general health allows participation in the study. The screening process includes blood tests, physical examinations, memory tests, questionnaires, an MRI scan, and a spinal tap.

Treatment

Each participant will take the study drug once a day for the first 2 weeks and then twice a day thereafter. The duration of treatment is 104 weeks. Approximately 9 visits to the research center are planned throughout the study. During a few visits, questionnaires and neuropsychological examinations will be done, blood tests, physical examinations, and sometimes an MRI scan and/or spinal tap will take place.

Optional sub-study: Participants may choose to participate in a sub-study that assesses how the study drug changes in the blood over time. Multiple blood samples are taken during this visit for 8 hours.

Follow-up

After completion of the treatment phase, participants will be followed for up to 4 weeks and will return to the study center for a final check-up, including a side-effect check-up and physical examination.

Who can participate?

  • You have been diagnosed with Alzheimer’s disease and are in an early stage of the disease
  • You are between 50 and 80 years old
  • Medication related to Alzheimer’s disease is permitted, provided it is stable 4 weeks prior to screening
  • You have someone close to you/a caregiver, who can act as a research partner, to help you and to answer questions about your health and functioning. Participation in the study will take approximately 2 years in total.

Take action against Alzheimer’s. Sign up to participate.

Latest Dementia trials

Filter

All trialsAlzheimer

Alnylam

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug ALN-APP is for the treatment of participants with MCI or mild dementia due to early onset Alzheimer’s disease, where the disease began before the participant was 65 years old. The study compares the effect of the new drug ALN-APP with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered through an injection into the fluid surrounding the spinal cord.

audience18+

levelAlzheimer’s or mild dementia due to early onset Alzheimer’s disease

duration152 weeks

locationAmsterdam

All trialsAlzheimer

REMAD 02

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug REM0046127 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug REM0046127 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

audience50 - 85 years

levelMild to moderate Alzheimer's disease

duration9 weeks

locationAmsterdam

All trialsAlzheimer

APOLLOE4

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug ALZ-801 is for the treatment of participants with early-stage Alzheimer’s disease and ApoE4/4 genotype. The study compares the effect of the new drug ALZ-801 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is taken in the form of a tablet.

audience50 - 80 years

level Early-stage Alzheimer’s disease and ApoE4/4 genotype

duration93 weeks

locationAmsterdam, Den Bosch, and Zwolle